查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1574759

硬纤维瘤市场：按药物类型、治疗类型、最终用户、年龄组、肿瘤部位分类 - 全球预测 2025-2030

Desmoid Tumors Market by Drug Type (Anti-Hormonal Therapy, Chemotherapy, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)), Treatment Type (Cryoablation, Radiation Therapy, Surgery), End User, Age Group, Tumor Location - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

硬纤维瘤市场2023年估值为25.8亿美元，预计2024年将达27.2亿美元，复合年增长率为5.83%，到2030年将达到38.4亿美元。

硬纤维瘤，也称为侵袭性纤维瘤病，是罕见的非转移性软组织肿瘤，由结缔组织产生并表现出浸润性生长模式。了解硬纤维瘤的市场范围需要认识到由于治疗选择有限且对患者生活品质产生重大影响而需要标靶治疗。主要用途包括手术切除、荷尔蒙疗法、非类固醇消炎剂(NSAID)、放射线治疗以及最近使用的标靶药物和化疗。最终用户包括专门从事肿瘤学和罕见疾病的医院、诊所和研究中心。影响市场的关键成长要素包括对硬纤维瘤认识和诊断的提高、分子生物学的进步导致了 CTNNB1 基因等基因突变的识别，以及针对特定分子标靶的新型疗法的开发。

主要市场统计
基准年[2023] 25.8亿美元
预测年份 [2024] 27.2亿美元
预测年份 [2030] 38.4亿美元
复合年增长率（%） 5.83%

潜在的市场机会在于增加对标靶治疗和个人化医疗研发的投资。新分子疗法和人工智慧主导的药物发现平台的使用为技术创新提供了肥沃的土壤。此外，製药公司对罕见疾病市场的兴趣日益浓厚，为希望利用治疗方案创新的新参与企业提供了充足的潜力。然而，该市场面临诸如硬纤维瘤病理生理学的复杂性、影响盈利的患者群体有限以及研发成本高等限制。此外，克服孤儿药的监管挑战可能是一个主要瓶颈。

利用基因组定序的进步来开发个人化治疗方法并优化非侵入性诊断技术是实现业务成长创新的最佳途径。探索与学术机构和生物技术公司的合作伙伴关係可以释放更多的研究见解并加速研发。硬纤维瘤市场的特点是医疗需求未满足的利基市场很高，但随着治疗方法的发展变得更加有效和精确，该市场有望成长。为了取得成功，我们必须专注于策略联盟，扩大全球意识计划，并投资于突破性发现，以提高治疗效果和市场渗透率。

市场动态：揭示快速发展的硬纤维瘤市场的关键市场洞察

供需的动态交互作用正在改变硬纤维瘤市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 加强诊断技术，实现早期发现并改善治疗策略
    • 发展针对个别硬纤维瘤概况的个人化医疗方法
    • 越来越注重以病人为中心的照护和支援服务，以提高生活品质
    • 扩大临床试验招募范围，为硬纤维瘤提供最先进治疗
  • 市场限制因素
    • 意识下降与误诊
  • 市场机会
    • 利用人工智慧和机器学习进行硬纤维瘤的早期检测和治疗计划
    • 製药公司与研究机构合作，加速开发硬纤维瘤新治疗方案
    • 加强公众意识宣传活动，并专注于硬纤维瘤的早期诊断和可用治疗方案
  • 市场挑战
    • 严格的核准和监管流程

波特的五力：驾驭硬纤维瘤市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解硬纤维瘤市场的外部影响

外部宏观环境因素在塑造硬纤维瘤市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解硬纤维瘤市场的竞争格局

硬纤维瘤市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵硬纤维瘤市场供应商的绩效评估

FPNV定位矩阵是评估硬纤维瘤市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製硬纤维瘤市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对硬纤维瘤市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 改进的诊断技术可以实现早期检测并改进治疗策略
      • 开发针对硬纤维瘤个别特征的个人化医疗方法
      • 注重以病人为中心的照护和支援服务，提高生活品质
      • 扩大临床试验招募范围并提供尖端的硬纤维瘤治疗方法
    • 抑制因素
      • 缺乏认识与误诊
    • 机会
      • 利用人工智慧和机器学习进行硬纤维瘤的早期检测和治疗计划
      • 製药公司和研究机构合作加速新治疗方法的开发
      • 加强宣传宣传活动，重点关注硬纤维瘤的早期诊断和可用治疗方案
    • 任务
      • 严格的核准和监管流程
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类型分類的硬纤维瘤市场

  • 抗荷尔蒙荷尔蒙疗法
  • 化疗
  • 非类固醇消炎剂(NSAID)

第七章依治疗类型分類的硬纤维瘤市场

  • 冷冻疗法
  • 放射治疗
  • 外科手术

第 8 章硬纤维瘤市场：依最终用户分类

  • 门诊手术中心
  • 医院
  • 专科诊所

第九章硬纤维瘤市场：依年龄组

  • 成人用
  • 老年病
  • 小儿科

第10章依肿瘤部位分類的硬纤维瘤市场

  • 腹部
  • 腹部外
  • 腹膜内

第十一章美洲硬纤维瘤市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区硬纤维瘤市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的硬纤维瘤市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-535C629188EE

The Desmoid Tumors Market was valued at USD 2.58 billion in 2023, expected to reach USD 2.72 billion in 2024, and is projected to grow at a CAGR of 5.83%, to USD 3.84 billion by 2030.

Desmoid tumors, also known as aggressive fibromatosis, are rare, non-metastasizing soft tissue tumors that arise from the connective tissue and exhibit an infiltrative growth pattern. Understanding the market scope for desmoid tumors involves recognizing the necessity for targeted therapies, given the limited treatment options and significant impact on patient quality of life. Applications primarily include surgical resections, hormonal therapies, NSAIDs, radiation therapy, and more recently, the use of targeted agents and chemotherapy. End-users encompass hospitals, clinics, and research centers focused on oncology and rare diseases. Key growth factors influencing the market include increased awareness and diagnosis of desmoid tumors, advances in molecular biology that have led to the identification of genetic mutations like the CTNNB1 gene, and the ongoing development of novel therapeutics aimed at specific molecular targets.

KEY MARKET STATISTICS
Base Year [2023] USD 2.58 billion
Estimated Year [2024] USD 2.72 billion
Forecast Year [2030] USD 3.84 billion
CAGR (%) 5.83%

The market's potential opportunities lie in increasing investments in research and development for targeted therapies and personalized medicine. Emerging molecular therapies and the use of AI-driven drug discovery platforms present fertile grounds for innovation. Furthermore, the growing interest in rare disease markets by pharmaceutical companies provides ample potential for new entrants aiming to capitalize on innovation in treatment options. However, the market faces limitations such as the complex nature of desmoid tumor pathophysiology, limited patient populations that affect profitability and high R&D costs. Additionally, navigating regulatory challenges for orphan drugs can be a significant bottleneck.

For business growth, the best avenues of innovation include leveraging advancements in genomic sequencing to develop personalized treatment regimens and optimizing non-invasive diagnostic techniques. Exploring partnerships with academic institutions and biotech firms may unlock further research insights and speed up therapeutic development. The desmoid tumor market is characterized by its niche nature with high unmet medical needs but is poised for growth as treatments evolve to become more effective and precise. To thrive, businesses should focus on strategic alliances, expand global awareness programs, and invest in breakthrough discoveries to enhance therapeutic outcomes and market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Desmoid Tumors Market

The Desmoid Tumors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Enhanced diagnostic techniques leading to earlier detection and improved treatment strategies
    • Development of personalized medicine approaches tailored to individual desmoid tumor profiles
    • Elevated focus on patient-centric care and support services improving quality of life
    • Expanding clinical trial enrollments providing access to cutting-edge therapies for desmoid tumors
  • Market Restraints
    • Limited awareness and misdiagnosis
  • Market Opportunities
    • Utilization of artificial intelligence and machine learning for early detection and treatment planning in Desmoid tumors
    • Collaboration between pharmaceutical companies and research institutions to accelerate the development of new treatment options for Desmoid tumors
    • Enhanced public awareness campaigns focusing on early diagnosis and available treatment options for Desmoid tumors
  • Market Challenges
    • Stringent approval and regulatory process

Porter's Five Forces: A Strategic Tool for Navigating the Desmoid Tumors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Desmoid Tumors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Desmoid Tumors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Desmoid Tumors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Desmoid Tumors Market

A detailed market share analysis in the Desmoid Tumors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Desmoid Tumors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Desmoid Tumors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Desmoid Tumors Market

A strategic analysis of the Desmoid Tumors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Desmoid Tumors Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Incyte Corporation, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Roche, Sanofi, SpringWorks Therapeutics, Takeda Pharmaceutical, and Teva Pharmaceutical.

Market Segmentation & Coverage

This research report categorizes the Desmoid Tumors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Anti-Hormonal Therapy, Chemotherapy, and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
  • Based on Treatment Type, market is studied across Cryoablation, Radiation Therapy, and Surgery.
  • Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
  • Based on Age Group, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Tumor Location, market is studied across Abdominal, Extra-Abdominal, and Intra-Abdominal.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Enhanced diagnostic techniques leading to earlier detection and improved treatment strategies
      • 5.1.1.2. Development of personalized medicine approaches tailored to individual desmoid tumor profiles
      • 5.1.1.3. Elevated focus on patient-centric care and support services improving quality of life
      • 5.1.1.4. Expanding clinical trial enrollments providing access to cutting-edge therapies for desmoid tumors
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and misdiagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Utilization of artificial intelligence and machine learning for early detection and treatment planning in Desmoid tumors
      • 5.1.3.2. Collaboration between pharmaceutical companies and research institutions to accelerate the development of new treatment options for Desmoid tumors
      • 5.1.3.3. Enhanced public awareness campaigns focusing on early diagnosis and available treatment options for Desmoid tumors
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent approval and regulatory process
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Desmoid Tumors Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Anti-Hormonal Therapy
  • 6.3. Chemotherapy
  • 6.4. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

7. Desmoid Tumors Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Cryoablation
  • 7.3. Radiation Therapy
  • 7.4. Surgery

8. Desmoid Tumors Market, by End User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Desmoid Tumors Market, by Age Group

  • 9.1. Introduction
  • 9.2. Adult
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Desmoid Tumors Market, by Tumor Location

  • 10.1. Introduction
  • 10.2. Abdominal
  • 10.3. Extra-Abdominal
  • 10.4. Intra-Abdominal

11. Americas Desmoid Tumors Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Desmoid Tumors Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Desmoid Tumors Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie
  • 2. Amgen
  • 3. AstraZeneca
  • 4. Bayer
  • 5. Blueprint Medicines
  • 6. Bristol-Myers Squibb
  • 7. Celgene Corporation
  • 8. Eli Lilly and Company
  • 9. Gilead Sciences
  • 10. GlaxoSmithKline
  • 11. Incyte Corporation
  • 12. Johnson & Johnson
  • 13. Merck & Co.
  • 14. Novartis
  • 15. Pfizer
  • 16. Roche
  • 17. Sanofi
  • 18. SpringWorks Therapeutics
  • 19. Takeda Pharmaceutical
  • 20. Teva Pharmaceutical

LIST OF FIGURES

  • FIGURE 1. DESMOID TUMORS MARKET RESEARCH PROCESS
  • FIGURE 2. DESMOID TUMORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DESMOID TUMORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DESMOID TUMORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DESMOID TUMORS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DESMOID TUMORS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES DESMOID TUMORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES DESMOID TUMORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. DESMOID TUMORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. DESMOID TUMORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DESMOID TUMORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DESMOID TUMORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DESMOID TUMORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DESMOID TUMORS MARKET DYNAMICS
  • TABLE 7. GLOBAL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DESMOID TUMORS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DESMOID TUMORS MARKET SIZE, BY CRYOABLATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DESMOID TUMORS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DESMOID TUMORS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DESMOID TUMORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DESMOID TUMORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DESMOID TUMORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DESMOID TUMORS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DESMOID TUMORS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DESMOID TUMORS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DESMOID TUMORS MARKET SIZE, BY ABDOMINAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DESMOID TUMORS MARKET SIZE, BY EXTRA-ABDOMINAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DESMOID TUMORS MARKET SIZE, BY INTRA-ABDOMINAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES DESMOID TUMORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
  • TABLE 236. DESMOID TUMORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 237. DESMOID TUMORS MARKET, FPNV POSITIONING MATRIX, 2023